Table 2.
Clinical features of 13 MG patients with a discontinuation of eculizumab therapy.
| No./age (years)/sex | Disease duration (months) | MG subset | Worst MGFA classification | Worst quantitative MG | Duration of eculizumab treatment (months) | Causes of discontinuation |
|---|---|---|---|---|---|---|
| #1/50/F | 47 | EOMG | III | 18 | 12 | Death (cervical cancer) |
| #2/84/F | 72 | LOMG | III | 27 | 34 | Death (cerebral infarction) |
| #3/32/F | 125 | EOMG | V | 31 | 1 | Adverse effect (dizziness) |
| #4/75/F | 41 | LOMG | V | 22 | 3 | Adverse effect (severe infection) |
| #5/37/M | 108 | TAMG | V | 16 | 33 | No effect |
| #6/41/M | 26 | TAMG | V | 18 | 13 | No effect |
| #7/47/F | 168 | TAMG | III | 19 | 6 | No effect |
| #8/48/M | 83 | TAMG | IV | 23 | 5 | No effect |
| #9/60/F | 396 | EOMG | II | 12 | 39 | No effect |
| #10/62/F | 196 | TAMG | IV | 20 | 8 | No effect |
| #11/23/F | 89 | EOMG | III | 14 | 21 | Minimal manifestations |
| #12/36/F | 66 | TAMG | III | 19 | 10 | Minimal manifestations |
| #13/62/F | 30 | TAMG | IV | 9 | 17 | Minimal manifestations |
EOMG, early onset MG; LOMG, late‐onset MG; MG, myasthenia gravis; MGFA, MG Foundation of America; TAMG, thymoma‐associated MG.